Description

The 67G ANIRIDIA IOL by Morcher is a specialized intraocular lens designed to address the unique needs of patients with aniridia or partial aniridia, whether congenital or resulting from ocular trauma. This innovative lens is crafted to enhance visual acuity and reduce glare, providing significant benefits for those with iris deficiency.

Implantation Versatility

The lens is typically implanted in the capsular bag but offers flexibility with options for sulcus or scleral fixation. Scleral fixation is recommended using 9-0 double-armed prolene sutures with spatula needles, ensuring secure placement tailored to individual patient needs.

Advanced Design

• Biconvex Structure: The lens features a biconvex design with a central transparent optic zone measuring 5.0 mm, surrounded by a black peripheral diaphragm.
• Adjustable Diaphragm: The diaphragm can be adjusted from 3.0 to 10.0 mm, allowing for customized light management.

Dimensions and Materials

• Total Diameter: 12.5 mm
• Optic Diameter: 3.0 mm
• Diaphragm Diameter: 10.0 mm

Constructed from clear poly(methyl methacrylate) (PMMA) for the optic and black PEMA (co-polymer) for the diaphragm, the lens ensures durability and optimal performance.

Optical Properties

The lens offers a standard diopter range from 10.0 to 30.0 D in 0.5 D increments, with additional ranges available upon request. It includes a theoretical standard diopter of 22.0 D, a refractive index of 1.49, and an integrated UV filter.

Surgical Considerations

Implantation requires a corneal incision greater than 10.0 mm, with at least 11 mm recommended. This consideration is crucial for surgeons planning the procedure.

Clinical Benefits

Clinical outcomes have demonstrated significant improvements in best-corrected visual acuity and a reduction in glare disability. The lens has shown a low incidence of mild postoperative anterior uveitis and no reported cases of secondary glaucoma, highlighting its favorable safety profile.

The 67G ANIRIDIA IOL stands as a remarkable solution for enhancing visual outcomes in patients with iris deficiency, backed by Morcher's commitment to quality and innovation.